Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
RCSB PDB - 6JX0: Crystal structure of EGFR 696-1022 T790M in complex ...
RCSB PDB - 6JXT: Crystal structure of EGFR 696-1022 WT in complex with ...
阿斯利康的双抗ADC药物在华申请临床获受理（附双抗ADC汇总）_治疗_研究_肿瘤
ADC新药“大闹”AACR医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
tilatamig samrotecan (AZD9592) / AstraZeneca
阿斯利康双抗（EGFRxcMET)ADC有何启示医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
技术前沿 | 双抗ADC的CMC工艺开发挑战与解决方案 #万物偶联 抗体偶联药物（Antibody-Drug Conjugate, ADC ...
Frontiers | Identifying optimal tumor-associated antigen combinations ...
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
A Comprehensive Introduction to Bispecific ADCs | AxisPharm
Expanding new trends and technologies in ADC therapeutics
双抗ADC：1+1>2 点击上方的 行舟Drug 添加关注 前言 抗体偶联药物（ADC）包括抗体、连接子和细胞毒性有效载荷。与传统化疗相比 ...
The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB ...
AACR2023| ADC药物及可用临床前动物模型 - 知乎
阿斯利康也“Follow”第一三共
How does AstraZeneca's PARP inhibitor differentiate?
阿斯利康EGFR/c-Met ADC在华申报临床 3月9日，据CDE官网公示， 阿斯利康 ADC药物AZD9592在华申报临床。AZD9592 ...
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in ...
Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate ...
Frontiers | A narrative review of antibody–drug conjugates in EGFR ...
EGFR敏感突变肺癌新药临床试验：EGFR/c-Met双靶点ADC药物AZD9592-印塔健康官网
Antibody-drug Conjugate Information | ADCdb
【AACR 2023】ADC药物”角力”AACR - 自主发布 - 资讯 - 生物在线
Journal of Medicinal Chemistry | Vol 63, No 23
第4款双抗获批：来自强生EGFR/cMET|FDA|强生|双抗|获批|数据|肿瘤|-健康界
Frontiers | Bispecific NK-cell engager targeting BCMA elicits stronger ...
Phase Ib study of afatinib plus standard-dose cetuximab in patients ...
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New ...
Tilatamig samrotecan (AZD9592) | ADC | MedChemExpress
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate ...
ADCdb: the database of antibody-drug conjugates
P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a ...
Frontiers | Targeting tumor-associated macrophages with STING agonism ...
双抗ADC全球在研格局 ADC药物在过去十多年间已取得了长足的进展，自2000年第一款药物Mylotarg上市，ADC已历经了三代。截止目前 ...
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance ...
2023AACR | ADC药物一览，多款双抗ADC亮相，恒瑞、石药、Seagen众星云集 2023年第114届美国癌症研究协会年会(AACR ...
阿斯利康三款1类新药在中国获批临床
医药魔方
Combination of T cell-redirecting bispecific antibody ERY974 and ...
API SYNTHESIS INTERNATIONAL: AZD 9291, Osimertinib, Third-generation ...
EGFR-Targeted Antibody–Drug Conjugate to Different Aminobisphosphonates ...
(A) A portion of the KEGG pathway map of nicotinate and nicotinamide ...
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective ...
In vivo antitumor efficacy of AZD9291 in subcutaneous xenograft models ...
EGFR signaling pathway - Blog
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：子宫内膜癌，恶性实体肿瘤，转移性子宫内膜恶性肿瘤 ...
Strategy to develop an effective EGFR ADC. | Download Scientific Diagram
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC ...
EGFR ADC药物征战NSCLC 2417字7图，阅读大约需要7分钟。文章首发于丰硕创投，欢迎朋友圈与微信转发。公众号及其它平台转载请后台 ...
Bispecifics – Expanding the potential of immunotherapies - Fusion ...
AZ7550, an Active Metabolite of AZD9291 (EGFR TKI), Inhibits the ...
EGFR/c-MET双抗一线治疗NSCLC III期研究成功 EGFR/c-MET双抗组合疗法一线线治疗NSCLC III期研究成功2023年 ...
Cell-free synthesis of functional antibody fragments to provide a ...
强生EGFR/c-MET双抗两项III期成功，隐忧难解，阿斯利康ADC能否逆袭 EGFR/c-MET双抗组合疗法二线治疗NSCLC III期 ...
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell ...
AACR 2023 XDC合集（一）|抗体药物|CDCP1|造血干细胞|癌症|-健康界
Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ...
AZD-9291 | CAS:1421373-65-0 | Mutated forms EGFR inhibitor | High ...
首次亮相！恒瑞医药两款ADC新药临床数据披露，抗肿瘤活性优异_摩熵医药(原药融云)
双抗ADC靶点介绍及在研药物研究进展-缔码生物
Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药-MedSci.cn
AZD-9592 - Drug Targets, Indications, Patents - Synapse
New EGFR inhibitor AZD9291 shows promising activity in treatment ...
Structural Basis of AZD9291 Selectivity for EGFR T790M | Journal of ...
从EGFR选择性看百利天恒双抗ADC|NSCLC|EGFR|HER3|ADC|ORR|抗体|靶点|-健康界
Popular Targets in the Bispecific ADC Pipeline-DIMA BIOTECH
High efficacy of third generation EGFR inhibitor AZD9291 in a ...
Trop2 ADC肺癌III期临床达PFS主要终点，浅谈Trop2 ADC研发进展|Trop2|NSCLC|ADC|PFS|DCR|乳腺癌 ...
Development of a bispecific antibody targeting PD-L1 and TIGIT with ...
阿斯利康EGFR/C-Met双靶点ADC——AZD9592专利公开，EGFR端亲和力高低成为重要考量因素医药新闻-ByDrug-一站式医药资源 ...
阿斯利康AZD9592获批临床，EGFR/c-MET双靶点药物究竟有何魅力？|观点_深圳热线
Full article: Theoretical validation of some third-generation epidermal ...
【双抗布局】——EGFR / c-MET：大厂必争的肺癌高地 - 知乎
Protein Kinase Dna Extraction at Jessica Fly blog
阿斯利康FRα ADC在华申报临床 8月25日，CDE官方显示， 阿斯利康 提交AZD5335的临床试验获得受理。AZD5335 是由FRα ...
(PDF) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated ...
Self-optimisation of the final stage in the synthesis of EGFR kinase ...
Osimertinib (AZD-9291) | Mutant-Selective EGFR Inhibitor | MedChemExpress
奥西耐药后的“给力”答案：阿斯利康AZD9592，EGFR/c-MET双靶点ADC，客观缓解率超越70%，开启临床试验招募
AZD 9291 Supplier | CAS 1421373-65-0 | AZD9291 | Tocris Bioscience
